Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / IMMX - Immix Biopharma gets review board nod to enroll kids in upcoming cancer therapy trial

IMMX - Immix Biopharma gets review board nod to enroll kids in upcoming cancer therapy trial

Immix Biopharma Inc.
  • Immix Biopharma ( NASDAQ: IMMX ) on Friday said it had got an approval from an institutional review board to enroll children in its upcoming clinical trial of its IMX-110 therapy for the treatment of rhabdomyosarcoma.
  • Rhabdomyosarcoma is a rare type of cancer that forms in soft tissue and can occur at any age, though it mostly affects children.
  • "Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher," IMMX said in a statement .
  • The company is also pursuing an approval of IMX-110 to treat soft tissue sarcoma in adults.
  • IMMX stock was up 2% at $0.78 in morning trading.

For further details see:

Immix Biopharma gets review board nod to enroll kids in upcoming cancer therapy trial
Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...